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ABSTRACT: Leber congenital amaurosis (LCA) is a se-
vere autosomal-recessive retinal dystrophy leading to congen-
ital blindness. A recently identified LCA gene is NMNAT1,
located in the LCA9 locus. Although most mutations in blind-
ness genes are coding variations, there is accumulating evidence
for hidden noncoding defects or structural variations (SVs).
The starting point of this study was an LCA9-associated con-
sanguineous family in which no coding mutations were found
in the LCA9 region. Exploring the untranslated regions of
NMNAT1 revealed a novel homozygous 5′UTR variant, c.-
70A>T. Moreover, an adjacent 5′UTR variant, c.-69C>T,
was identified in a second consanguineous family displaying a
similar phenotype. Both 5′UTR variants resulted in decreased
NMNAT1 mRNA abundance in patients’ lymphocytes, and
caused decreased luciferase activity in human retinal pigment
epithelial RPE-1 cells. Second, we unraveled pseudohomozy-
gosity of a coding NMNAT1 mutation in two unrelated LCA
patients by the identification of two distinct heterozygous par-
tial NMNAT1 deletions. Molecular characterization of the
breakpoint junctions revealed a complex Alu-rich genomic ar-
chitecture. Our study uncovered hidden genetic variation in
NMNAT1-associated LCA and emphasized a shift from coding
to noncoding regulatory mutations and repeat-mediated SVs in
the molecular pathogenesis of heterogeneous recessive disor-
ders such as hereditary blindness.
Hum Mutat 36:1188–1196, 2015. Published 2015 Wiley Period-
icals, Inc.∗
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Introduction
Leber congenital amaurosis (LCA; MIM #204000) is the earli-
est and most severe inherited retinal dystrophy, causing profound
visual deficiency, nystagmus, and an undetectable or severely re-
duced electroretinogram (ERG) in the 1st year of life [Leber, 1869;
Franceschetti and Dieterle, 1954]. The disease may develop as a
cone-rod (type I) or rod-cone dystrophy (type II), with associated
features further impairing visual function [Hanein et al., 2004]. So
far, 19 disease genes have been associated with autosomal-recessive
LCA (RetNet). The encoded proteins function in retina-specific as
well as general processes [den Hollander et al., 2008]. In recent
years, genetic causes have been found in up to 70% of cases, fa-
cilitated by massively parallel sequencing (MPS) technologies such
as targeted resequencing of linkage intervals or whole-exome se-
quencing (WES) [Neveling et al., 2013]. Although most mutations
underlying LCA are located in coding regions, there is accumulat-
ing evidence for genetic defects in noncoding regions such as deep
intronic mutations or regulatory mutations in enhancers, promot-
ers, or untranslated regions (UTRs). A striking example is a deep
intronic mutation of CEP290, accounting for 15% of congenital
blindness in Europe [Coppieters et al., 2010].
In 2012, four groups independently identified the gene encod-
ing nicotinamide nucleotide adenylyltransferase 1 (NMNAT1; MIM
#608700) as a new LCA disease gene through WES [Chiang et al.,
2012; Falk et al., 2012; Koenekoop et al., 2012; Perrault et al., 2012].
Interestingly, all studies reported severe phenotypes with macular
coloboma or atrophic macular lesions in almost all cases, repre-
senting one of the strongest genotype–phenotype correlations ever
observed inLCA. Subsequent sequencing of theNMNAT1 coding re-
gion in 740 additional prescreened LCA cases revealed homozygous
or compound heterozygous mutations in 45 probands (6.1%) from
different origins [Chiang et al., 2012; Falk et al., 2012; Koenekoop
et al., 2012; Perrault et al., 2012]. The majority of NMNAT1 muta-
tions causing LCA are missense changes, predicted to alter protein
structure and/or abolish function based on the NMNAT1 crystal
structure [Zhou et al., 2002], and in vivo aswell as in vitro enzymatic
activity assays [Chiang et al., 2012; Falk et al., 2012; Koenekoop et al.,
2012; Perrault et al., 2012; Siemiatkowska et al., 2014]. Until now,
only five nonsense, three frameshift, and one splice-site mutation
have been identified. In addition, the segregation of a read-through
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mutation in theoriginal LCA9 family sustained the elucidationof the
last remaining LCA locus [Keen et al., 2003; Koenekoop et al., 2012].
Thus far, only coding NMNAT1mutations have been reported.
NMNAT1, which is localized to the nucleus, catalyzes NAD+
synthesis in the last step of a salvage synthesis pathway that
recycles nicotinamide back to NAD+. Both a fusion protein
(Ube4b/Nmnat1) from a spontaneous mouse model [Coleman and
Freeman, 2010] and NMNAT1 overexpression protect axons from
degeneration [Zhu et al., 2013; Fang et al., 2014], opening thera-
peutic perspectives for retinal neurodegeneration.
Here, we aimed to identify the hidden genetic defect in a LCA9-
associated family. The absence of a NMNAT1 coding mutation
prompted us to explore the UTRs, revealing a novel 5′UTR vari-
ant, c.-70A>T. Subsequently, a second adjacent 5′UTR variant,
c.-69C>T, was identified in an unrelated family with LCA and mac-
ular involvement. Functional studies of both 5′UTR variants suggest
a loss-of-function effect. Second, we aimed at unraveling the pseu-
dohomozygosity of a coding NMNAT1 mutation in two unrelated
patients with a similar form of LCA, leading to the identification
of two distinct heterozygous partial deletions of NMNAT1. Our
study uncovers, for the first time, hidden genetic variation and a
complex molecular pathogenesis of NMNAT1-associated LCA and
is exemplary for congenital blindness and for other heterogeneous
autosomal-recessive diseases in general.
Materials and Methods
Ethics Statement
This study was conducted following the tenets of the Declara-
tion of Helsinki and ethical approval was given by the local ethics
committee (Ghent University Hospital).
Patients
This study included 101 consenting subjects initially diagnosed
with LCA (74) or early-onset retinal dystrophy (EORD) (27) and re-
ferred formolecular testing by anophthalmologist and/or geneticist.
All affected individuals were subjected to standard ophthalmologic
evaluation, among which visual acuity measurement, fundoscopy,
ERG, infrared, visual field assessment, and autofluorescence imag-
ing.
Genomic DNA (gDNA) was extracted from leukocytes using
the Gentra Puregene Blood Kit (QIAGEN Benelux BV, Antwerp,
Belgium), whereas RNA was extracted from leukocytes using the
RNeasy Mini kit and the RNase-Free DNase set (Qiagen), followed
by cDNA synthesis (iScript cDNA Synthesis kit; Bio-Rad Laborato-
ries NV, Temse, Belgium). A selection of lymphocyte cultures were
treated with puromycin to block nonsense-mediated decay. If avail-
able, parents and/or siblings were also genotyped. Most probands
previously underwent at least LCA chip analysis, testing 344 to
780 mutations in eight to 15 LCA and EORD genes (LCA chip
Versions 2004–2012; Asper Ophthalmics, Tartu, Estonia, Estonia)
(http://www.asperbio.com).
Identity-by-Descent Mapping in F1
At the onset of this study, gDNAwas available of two affected cases
(IV:1 and IV:2) of F1, originating fromNiger. These individuals un-
derwent genome-wide identity-by-descent (IBD) mapping using
Affymetrix GeneChip Human Mapping 250K Nsp arrays accord-
ing to manufacturer protocols (DNAVision, Charleroi, Belgium).
Single-nucleotide polymorphism (SNP) genotypes were analyzed
with PLINK [Purcell et al., 2007]. A healthy sibling (IV:3) was born
later andunderwent SNPgenotyping later in the course of this study.
MPS in F1
The four largest IBD regions common between both oldest af-
fected siblings of F1 (IV:1 and IV:2) were selected for MPS using
the NimbleGen Sequence Capture 385K array. The array design
was based on the RefSeq (NCBI), AceView (NCBI), and RNAgene
(UCSC) resources and included all coding exons, 50 bp upstream
intronic sequence, 20 bpdownstream intronic sequence,UTRs (Ref-
Seq), and 500 bp upstream genomic region (putative promoter, Ref-
Seq) (NCBI36/hg18). Two samples enriched with this method, one
of which was the proband of F1, were sequenced on a Roche, Vil-
voorde, Belgium GS FLX Titanium run. The CLC Genomics Work-
bench (version 6.5; CLC bio, Aarhus, Denmark) was employed for
readmappingagainst thehumangenomereference sequence (NCBI,
GRCh37.p5), postmapping duplicate read removal, coverage anal-
ysis, and quality-based variant detection.
NMNAT1 Sequencing on gDNA and cDNA Level in F1 and F2
All probands underwent gDNA sequencing of exon 1, all coding
regions and intron–exon boundaries of NMNAT1. cDNA sequenc-
ing was carried out using intron-spanning amplicons in all individ-
uals of F1 and F2. PCR primers were designed with Primer3Plus
[Untergasser et al., 2007]. Sanger sequencing was performed using
the BigDye Terminator v3.1 Cycle Sequencing kit (Applied Biosys-
tems, ThermoFisher Scientific, Waltham, MA) on a 3730xl DNA
Analyzer (Applied Biosystems).
Evaluation of Sequence Changes
Mutation nomenclature uses numbering with the A of the ini-
tiation codon ATG as +1 (NM 022787.3) (http://www.hgvs.org/
mutnomen). All variants and individuals have been submitted to the
following locus-specific database: http://www.lovd.nl/NMNAT1. In
silico evaluation of novel NMNAT1 variants was done with the
Alamut mutation interpretation software v.2.3 (Interactive Biosoft-
ware, Rouen, France). Segregation analysis of disease alleles was per-
formed if possible, whereas gDNA obtained from unrelated healthy
individuals of Belgian origin (>173) was used as a control panel.
NMNAT1 and LZIC mRNA Quantification
Intron-spanning primer pairs for NMNAT1 and LZIC mRNA
quantification were designed using PrimerXL (http://www.
primerxl.org). qPCR-based mRNA quantification was performed
as previously described [Derveaux et al., 2010]. At least two ref-
erence genes were used for data normalization. Data analysis was
performed with qbase+ software (Biogazelle, Ghent, Belgium). P-
values were calculated in qbase+ using a two-sided two-sample t-test
with unequal variances. Six healthy controls were included in which
no mutations were identified following Sanger sequencing of exon
1, all coding regions, and intron–exon boundaries of NMNAT1.
Bisulfite Sequencing
Bisulfite conversion of DNA was performed using the EZ DNA
Methylation kit and the Human Methylated and Non-Methylated
DNA Set (Zymo Research, Freiburg, Germany), followed by Sanger
sequencing and analysis in SeqScape v2.5 (Applied Biosystems).
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Luciferase Assays
Three different luciferase constructs were used: one for the NM-
NAT1 promoter and two for the NMNAT1 5′UTR. For the pro-
moter construct, we used the commercially available NMNAT1
pLightSwitch Prom reporter vector, which was mutated to gen-
erate the c.-70A>T (F1) and c.-69C>T (F2) mutant constructs
(SwitchGear Genomics, La Hulpe, Belgium). For the 5′UTR con-
structs, wild-type and mutant DNA oligos (Integrated DNA Tech-
nologies, BVBA, Leuven, Belgium) were cloned into the pGL3 re-
porter vectors pGL3-prom and pGL3-basic (Promega Benelux BV,
Leiden, The Netherlands), the latter containing a minimal CMV
promoter sequence.
RPE-1 (human retinal pigment epithelial) cells were used to per-
form functional analysis. They were grown inDMEM-F12medium,
supplementedwith 10%FBSand1%penicillin/streptomycin (Ther-
moFisher Scientific, Waltham, MA Gibco, ThermoFisher Scientific,
Waltham, MA). RPE-1 cells were seeded 16 hr prior to transfection
at a density of 4.104 cells/cm2. Each experiment was performed in
six replicates in 96-well culture plates. Cells were transfected with
100 ng ofDNAperwell using fuGENE-HD(SwitchGearGenomics).
Forty-eight hours after transfection, cells were washed with PBS be-
fore lysis and firefly luciferase and renilla luciferase activities were
assessed by the Dual-Luciferase Reporter Assay System (Promega).
Luciferase results are reported as relative light units (RLU, i.e., the
ratio of the Renilla luciferase and firefly luciferase activities). Each
value is the mean of six independent experiments, and standard
error bar represent the standard error of the mean.
Copy-Number Variation Analysis
For each of the five exons, a qPCR amplicon was designed
(http://www.primerxl.org). Identified deletions were further delin-
eated at the 5′ and 3′ end using additional qPCR amplicons. qPCR-
based copy-number variation (CNV) analysis was performed as
previously described, using two reference genes for normalization
of the relative quantities [D’Haene et al., 2010]. Data analysis was
performed with qbase+ software (Biogazelle). The junction prod-
ucts were amplified with the iProof High-Fidelity DNA Polymerase
(Bio-Rad), followedby Sanger sequencingusing internal sequencing
primers.
Bioinformatic Analysis of the Deletion Junctions
Bioinformatic analysis of the deletions junctions was performed
as previously described [Verdin et al., 2013].
In short, known repetitive elements intersecting the breakpoints
were identified using the RepeatMasker track in the UCSC genome
browser, followed by BLAST2 (NCBI) analysis to determine the
percentage of sequence identity between the different elements. The
presence of DNA sequences leading to non-B DNA conformations
in the breakpoints was examined using the following tools: Re-
peatAround [Goios et al., 2006], QGRSMapper [Kikin et al., 2006],
and nBMST [Cer et al., 2012]. Finally, the presence of 40 previously
described sequence motifs was analyzed with Fuzznuc [Rice et al.,
2000; Abeysinghe et al., 2003].
Results
First NMNAT1 5′UTR Mutation in LCA9-Linked Family
The starting point of this study was a consanguineous family
from Niger (F1) in which all affected individuals suffered from
severe LCA with progressive macular involvement. Genome-wide
IBDmapping using SNP arrays in the two oldest affected individuals
of F1, IV:1 and IV:2, revealed four common regions larger than
3 Mb (Supp. Table S1). Two of these could be partially excluded
later when the healthy sibling (IV:3) was born, as the latter child was
homozygous for the same haplotype. Three regions remained in
total, together harboring 22.9 Mb and 321 genes. Interestingly, the
largest region contained the LCA9 locus (Supp. Fig. S1) [Keen et al.,
2003].
MPS of the IBD regionswas performed at the timewhen only IV:1
and IV:2 were available, and included capturing and resequencing
of all coding exons, intron–exon boundaries, UTRs, and putative
promoters of the four common IBD regions (Supp. Table S1). Of
the 1.6 Mb target region, 87.5% was covered by the NimbleGen
Sequence Capture 385K platform design considering an offset of
100 bp. MPS generated 539,559 reads, of which 463,208 (86%)
unique reads were aligned against the human genome reference
sequence (NCBI, GRCh37.p5), resulting in a minimal coverage of
10x and 20x for 93% and 85%, respectively, of the target regions.
In total, 6,153 variants were detected with a coverage and variant
allele frequency equal to or above 5x and 70%, respectively. Variants
were prioritized based on their predicted effect on the protein (non-
sense/frameshift > missense > silent) or splicing, and subsequently
subjected to segregation analysis in the family and control samples.
However, this approach did not allow the identification of the causal
defect.
Following the identification of NMNAT1 as the causal disease
gene for the LCA9 locus [Koenekoop et al., 2012], MPS data were
revisited and subjected to an in-depth analysis of the five exons of
NMNAT1, including the UTRs. Supp. Table S2 lists all NMNAT1
variants identified in the proband of F1 through MPS. Of the nine
variants, four were located in an intron, one upstream of the gene,
one in the 5′UTR and three in the 3′UTR. Two variants were novel,
with only one predicted to affect splicing, namely, c.-70A>T (Supp.
Fig. S2). This variant is located in exon 1, which is part of the 5′UTR,
and segregates with the disease in the family (Fig. 1).
Second Adjacent NMNAT1 5′UTR Mutation in Unrelated
Family
Sanger sequencing of the 5′UTR, all coding regions and intron–
exon boundaries ofNMNAT1 in 98 additional LCA (71) and EORD
(27) probands revealed potential pathogenic coding variants in five
LCA families (Supp. Table S3). Biallelic coding mutations were
found in F5, F6, and F7. In the probands of F8 and F9, however, only
a single heterozygous variant was identified. Unfortunately, no phe-
notype data are available for these two patients. In both individuals,
Sanger sequencing of the 5′UTR did not reveal a second mutation.
For F8, no DNAwas available anymore to performCNV analysis. In
F9, qPCR analysis did not reveal a CNV, pointing to other mutation
mechanisms in NMNAT1 or to the involvement of another retinal
disease gene.
Interestingly, a homozygous 5′UTR variant, c.-69C>T, was
found in F2, an unrelated consanguineous family from Morocco
(Table 1). This variant is located one nucleotide downstream of
c.-70A>T; however, unlike c.-70A>T, it is not predicted to affect
splicing (data not shown). The c.-69C>T variant was the only NM-
NAT1 variant identified in the proband of F2 and segregates with
disease. Similar to F1, the affected individuals of F2 display LCA
with progressive macular involvement, which is in agreement with
the typical NMNAT1-associated phenotype (Fig. 1).
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Figure 1. Segregation analysis, associated phenotype, and mRNA quantification of the NMNAT1 5′UTR mutations. A: Segregation analysis of
the c.-70A>T mutation in F1 and the c.-69C>T mutation in F2. B: Fundus picture of right eye of female patient IV:1 (F1) at age 7 years; note area
of atrophy of outer retinal layers with some intraretinal pigment migration and highlighted luteal pigment in macula; mottled aspect of peripheral
retinal pigment epithelium illustrates disease in outer retinal layers alternating with anatomically better preserved spots. C: Fundus picture of right
eye of male patient IV:2 (F2) at age 21 years; note large area of total retinal and choroidal atrophy in macular area; this area was smaller with
atrophy limited only to outer retinal layers but not choroid at age 7 years (data not shown); also note grayish area of outer retinal atrophy in retinal
periphery, with limited intraretinal pigment migration. D: qPCR quantification of NMNAT1 mRNA abundance on lymphocyte cDNA of all available
family members of F1 and F2, and six healthy controls. The abundance of NMNAT1 mRNA was significantly lower in the affected individuals of F1
in comparison with the controls (P = 5,473E-5). No significant difference was observed however in the affected individuals of F2 in comparison with
controls (P = 0.072) (unpaired t-test). Abbreviations used: C, control; F, family; M, mutant allele, +, wild-type allele; UTR, untranslated region.
Functional Assessment of c.-70A>T and c.-69C>T
NMNAT1 cDNA sequencing and quantification
Subsequent Sanger sequencing was performed on lymphocyte-
derived cDNA from all available family members of F1 and F2. As
c.-70A>T was predicted to affect splicing, lymphocyte cultures of
F1 were treated with and without puromycine, a protein synthe-
sis inhibitor used to prevent nonsense-mediated mRNA decay. No
splicing defects were identified. However, haplotype analysis at the
cDNAlevel of threeNMNAT1variantspreviously foundat thegDNA
level revealed allele-specific expression in theparents and thehealthy
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Table 1. NMNAT1 5′UTR Mutations and Copy-Number Variations Explaining Hidden Genetic Variation in This Study
Allele 1 Allele 2
Family Exon cDNA Protein Reference Exon/intron cDNA Protein Reference
F1 E1 (5′UTR) c.-70A>T p.? Novel E1 (5′UTR) c.-70A>T p.? Novel
F2 E1 (5′UTR) c.-69C>T p.? Novel E1 (5′UTR) c.-69C>T p.? Novel
F3 E5 c.709C>T p.Arg237Cys Falk et al. (2012);
Perrault et al. (2012)
NMNAT1 partial deletion (g.10039763 10056271del) (hg19) Novel
F4 E5 c.709C>T p.Arg237Cys Falk et al. (2012)
Perrault et al. (2012)
NMNAT1 partial deletion (g.10038285 10043034del) (hg19) Novel
Abbreviations used: F, family; E, exon; UTR, untranslated region.
sib of F1 (Supp. Fig. S3). This result was obtained in cells treated
with and without puromycine, suggesting that the genetic defect
has an effect prior to translation. In F2, cDNA was only available
from untreated lymphocyte cultures. As in F1, cDNA sequencing
showed allele-specific expression in both parents. In both families,
superposition of low sequence traces could be seen, representing
residual mutant mRNA (Supp. Fig. S3).
In order to quantifyNMNAT1mRNA abundance, qPCR analysis
was performed on cDNA of all available family members of F1 and
F2, and six healthy controls. This revealed a lowermRNAabundance
in the affected, homozygous individuals in comparison with the
healthy controls (Fig. 1D).
LZIC mRNA quantification in F1
TheNMNAT1 gene is transcribed from the forward DNA strand.
NMNAT1 mutations, c.-70A>T and c.-69C>T, are located 133 and
134 bp downstream of the 5′UTR of the LZIC gene (UCSC genes),
which is transcribed from the negative DNA strand and thus located
in a head-to-head orientation with NMNAT1 (Fig. 2B). The LZIC
protein is required for neuronal survival in zebrafish [Clements and
Kimelman, 2005]. Therefore, an effect on LZIC mRNA abundance
was assessed using qPCR analysis, which revealed no difference in
mRNA abundance between the affected individuals of F1 and six
healthy control individuals (Supp. Fig. S4).
In silico prediction of the effects of the 5 ′UTR mutations
Both 5′UTR mutations are located in exon 1, which is part of
a transcription unit of NMNAT1 according to several ENCODE-
integrated regulation tracks. In addition, bothmutations are located
in a CpG island encompassing exon 1 (Fig. 2A). 5′UTRs mutations
can cause aberrant mRNA instability or translational regulation
throughdifferentmechanisms.Weperformed an in silico evaluation
of the mutated and wild-type sequences that revealed a potential
loss of several transcription factor binding sites (Supp. Table S4),
potential disruption of secondary structures (Supp. Fig. S5), or
location in G-quadruplexes (Supp. Table S5).
Bisulfite sequencing
To determine whether the 5′UTR variants might affect methyla-
tion of theCpG island,we performed Sanger sequencing of bisulfite-
converted gDNA of all family members of F1, three control individ-
uals, and one methylated and one nonmethylated control sample
(Fig. 2A). No difference was seen in the methylation status of F1
in comparison with the healthy controls (data not shown). In all
individuals, each evaluated CpG nucleotide was unmethylated.
Luciferase assays
Figure 2B shows an overview of theNMNAT1 genomic locus. The
NMNAT1 gene contains five exons. The 5′UTR encompasses exon
1 and part of exon 2. The first two exons are separated by a large
intron of 28 kb. To study the potential effects of themutations on the
regulation ofNMNAT1 expression or on the stability/translatability
of its transcripts, we created three different luciferase constructs:
one for the putative NMNAT1 promoter and two for the NMNAT1
5′UTR. The promoter construct contained 1,020 bp of sequence
harboring exon 1 and an upstream region, followed by the Renilla
reporter gene RenSP (SwitchGear Genomics). In the two different
5′UTR constructs, the 5′UTR, consisting of exon 1 and part of exon
2, was cloned downstream of either an SV40 or CMV promoter,
followed by the firefly luciferase gene (pGL3-prom and pGL3-basic
reporter vectors; Promega) (Fig. 2B).
Figure 2C shows the expression of these constructs in human
retinal pigment epithelial RPE-1 cells. First, we assessed the activity
of the putative NMNAT1 promoter. The two mutated forms show
a decrease in luciferase activity (25% for c.-69>T and 33% for c.-
70A>T), suggesting that a single mutation is able to reduce the
promoter activity. Second, the WT or mutated 5′UTR were cloned
as described above with a strong promoter (SV40 or CMV). Again,
in both constructs, there is a significant decrease in luciferase activity
with the two mutated forms, c.-69C>T and c.-70A>T, relative to the
wild type.With pGL3-prom, containing a SV40 promoter, luciferase
activity is reduced with 72% for c.-69C>T and 32 % for c.-70A>T.
With pGL3-CMV, luciferase activity is reduced with 36% for c.-
69C>T and 22 % for c.-70A>T, respectively.
Structural Variations of NMNAT1
In two Japanese families (F3 and F4), pseudohomozygosity for
the same codingNMNAT1mutation c.709C>T p.(Arg237Cys) [Falk
et al., 2012; Perrault et al., 2012] was demonstrated [Suzuki et al.,
2014], suggesting hemizygosity due to a heterozygous deletion (Ta-
ble 1; Supp. Fig. S6A). Both probands showed LCA with macular
degeneration in both eyes at the time of diagnosis (age 3 months).
In the proband of F4, the macular degeneration was progressed at
the age of 4 months (Supp. Table S6).
Subsequently, CNV screening was performed using five qPCR as-
says, one for each exon. This revealed a heterozygous deletion of the
amplicons for exon 4 and 5 in the proband of F3 and of the amplicon
for exon 4 in the proband of F4 (Supp. Fig. S6B). Figure 3 shows
the delineation of both deletions using PCRwalking with additional
qPCR amplicons. Subsequently, the junction product was generated
using long-range PCR and underwent Sanger sequencing, revealing
partial gene deletions of 16.5 kb (F3) and 4.8 kb (F4), respectively.
Both CNVs segregated with disease in the families (Supp. Fig. S6C).
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Figure 2. Location and functional analysis of the NMNAT1 5′UTR mutations, c.-70A>T and c.-69C>T. A: Overview of a selection of the ENCODE
Integrated Regulation tracks aligning with exon 1. The bisulfite_sequencing custom track shows the region covered by the bisulfite sequencing
performed in F1. B: Overview of the NMNAT1 gene locus and luciferase reporter constructs. The NMNAT1 5′UTR consists of exon 1 and part of
exon 2, which are separated from each other by a large intron (28 kb). The promoter construct contains the NMNAT1 promoter upstream of a Renilla
luciferase gene. The 5′UTR constructs contain an SV40/CMV promoter, followed by the NMNAT1 5′UTR and a firefly luciferase gene. C: Results
luciferase assays. Upper panel: transcriptional activities of WT and mutated NMNAT1 promoter. Luciferase assays were performed in RPE-1 cells.
Relative lights units (RLU) correspond to the ratio of the activity of the Renilla reporter (RenSP) over that of the firefly luciferase reporter (internal
control of transfection efficiency, pGL3-CMV-empty). Lower panel: transcriptional activities of WT and mutated NMNAT1 5′UTR. RLU correspond
to the ratio of the activity of the firefly luciferase reporter over that of the Renilla reporter (internal control of transfection efficiency, pRL-RSV).
Statistical significance in Student’s t-tests: n.s., P.0.05; ∗: P,0.05; ∗∗, P,0.01, ∗∗∗, P,0.001.
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Figure 3. Molecular characterization of two distinct heterozygous NMNAT1 deletions. A: Overview of the NMNAT1 genomic locus, which is
scattered with Alu repeats. The Database of Genomic Variants contains one duplication. B: Refinement and delineation of both heterozygous
deletions at the nucleotide level. Deleted amplicons are indicated in green; amplicons with a normal copy number are indicated in blue. In F3, two
subsequent refinement rounds with seven additional qPCR amplicons in total (ampl_1–ampl_7) were needed to refine the deletion at both ends to
a region of 13.0–18.7 kb. Subsequent long-range PCR and Sanger sequencing revealed a deletion of 16.5 kb. In F4, refinement at the 5′ end (ampl_1
and ampl_2) delineated the deletion to a region of 1.5–6.7 kb. At the 3′ end, the deletion breakpoint appeared to be located between the p.Arg237Cys
mutation and the forward primer of the amplicon CNV_E5 (3′ UTR), as this amplicon was not deleted according to qPCR results (Supp. Fig. S6B).
Subsequent long-range PCR and Sanger sequencing revealed a deletion of 4.8 kb. For both deletions, the breakpoints regions are located in Alu
repeats. C: Alignment of the junction product with the 5′ and 3′ reference sequence revealed microhomology regions of 34 and 10 bp for F3 and F4,
respectively.
Bioinformatics Study of the Breakpoint Junctions
The breakpoints of the partialNMNAT1 deletions were subjected
to an extensive bioinformatic analysis to explore the local genomic
architecture and potential underlyingmechanisms (Supp. Table S7).
The deletion junctions displayed microhomology of 34 bp (F3) and
10 bp (F4) between their breakpoints (Fig. 3C). Based on these
observations, microhomology mediated break-induced replication
is a potential underlying mechanism. Interestingly, Alu elements
were observed at all breakpoints, consisting of AluY-AluY (F3) and
AluSx-AluSc (F4) combinations. Blast2 analysis showed a sequence
identity of 92% (F3) and 88% (F4) between the combined Alu re-
peats. Because of this similarity of theAlu elements involved and the
relatively short distance separating them, single-strand annealing is
also possible, although this is a minor mechanism in the formation
of structural variations (SVs) [Hastings et al., 2009].
Discussion
NMNAT1 is oneof themost recently identifiedLCAgenes (LCA9).
Thus far, eight studies listed 45 distinct mutations, all located in
the coding region or intron–exon boundaries of NMNAT1 [Chiang
et al., 2012; Falk et al., 2012; Koenekoop et al., 2012; Perrault et al.,
2012; Corton et al., 2013; Coppieters et al., 2014; Jin et al., 2014;
Siemiatkowska et al., 2014]. Here, we demonstrate for the first time
that both regulatory 5′UTR variations and SVs of NMNAT1 add to
the complex molecular pathogenesis of LCA.
The pathogenicity of the 5′UTR mutations, c.-70A>T and
c.-69C>T, identified in two unrelated families with a typical
NMNAT1-associated phenotype, has been substantiated by several
pieces of evidence: (1) segregation analysis, (2) allele-specific expres-
sion at the cDNA level, (3) decreased mRNA abundance in patients’
lymphocytes compared with healthy controls, and (4) decreased
luciferase activity of mutated constructs in retinal RPE-1 cells com-
pared with wild-type constructs (Figs. 1 and 2; Supp. Fig. S3). These
results suggest a loss-of-function effect of both 5′UTR mutations,
which is in line with the known NMNAT1 mutation spectrum.
Apart from a few nonsense and frameshift mutations, most muta-
tions are missense changes. For a selection of these, in vivo and/or
in vitro functional assays were performed, demonstrating reduced
enzymatic activity [Falk et al., 2012; Koenekoop et al., 2012]. In ad-
dition, we excluded an effect on expression of a neighboring gene,
LZIC (Supp. Fig. S4), and methylation changes of an overlapping
CpG island.The exactmolecular consequences of both5′UTRmuta-
tions onmRNA stability or translation efficiency remain to be stud-
ied. As both mutations are adjacent, an effect on secondary struc-
ture formation or disruption of a motif representing a DNA/RNA
protein-binding site seems plausible (Supp. Tables S4 and S5; Supp.
Fig. S5).
Interestingly, the occurrence of cis-acting variants affecting NM-
NAT1 expression levels has recently been put forward in another
context. Based on the high population frequency of p.Glu257Lys,
the most common NMNAT1 mutation, and nonpenetrance of this
mutation in a family with intellectual disability, a recent study hy-
pothesizes that p.Glu257Lys is a hypomorphic variant only causing
LCA in combination with more severe NMNAT1 mutations, or in
combination with trans- or cis-acting variants resulting in reduced
transcription. Moreover, two different haplotypes in NMNAT1 ho-
mozygotes for p.Glu257Lys suggest the presence of cis-acting factors
influencing expression [Siemiatkowska et al., 2014].
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Thus far, only 40%–70% of the retinal dystrophy cases can be
attributed to mutations in the known disease genes. Until now, it
was presumed that the remaining cases were caused bymutations in
novel disease genes. The widely applied high-throughput sequenc-
ing technologies did not yield the expected number of novel, fre-
quently mutated genes, however. This underscores the importance
of a much larger number than expected of less prevalent disease
genes, or, more likely, of hidden mutations in already known dis-
ease genes. These mutations might be balanced or unbalanced SVs,
deep intronic mutations, silent variants affecting splicing, or reg-
ulatory mutations in promoters, UTRs, and enhancers. Thus far,
only a handful of mutations affecting regulatory regions have been
identified in retinal dystrophies. A few examples are a homozygous
1.6 kb deletion encompassing 1 kb of the promoter region and the
first noncoding exon of LCA5 in autosomal-recessive LCA [denHol-
lander et al., 2007], two distinct heterozygous substitutions in the
3′UTR of CA4 in three families with autosomal-dominant/sporadic
retinitis pigmentosa [Yang et al., 2005; Tian et al., 2010], a heterozy-
gous substitution in the 5′UTR of PRPF31 in autosomal-dominant
retinitis pigmentosa [Rose et al., 2012], and a heterozygous 18-bp
deletion crossing the transcription start site of PRPF4 in autosomal-
dominant retinitis pigmentosa [Chen et al., 2014]. In most of these
studies, decreased mRNA abundance in patients’ blood cells and/or
decreased luciferase activity in vitro was shown, in agreement with
our findings.
Both the identification and interpretation of these categories of
mutations is extremely challenging. We initially failed to identify
the causal mutation in the largest IBD interval of family F1, de-
spite the inclusion of UTRs and putative promoter regions in our
custom enrichment design. Similarly, despite the inclusion of UTRs
in several commercial WES designs [Clark et al., 2011], only a few
UTR mutations in novel genes have been identified and function-
ally validated thus far using this approach [Cho et al., 2012; Semler
et al., 2012; Williamson et al., 2014]. The main reason for this is the
tremendous number of variants that should undergo data analysis
if UTRs would be kept within a standard variant-filtering pipeline.
In order to facilitate this process, novel high-throughput evaluation
tools are needed to evaluate this category of noncoding variants as
well.
In the second part of this study, we identified two different par-
tial deletions of the NMNAT1 gene following CNV analysis in two
families with pseudohomozygosity of a coding NMNAT1 mutation
(Supp. Fig. S6). Both deletions were delineated at the nucleotide
level, and a bioinformatics study revealed Alu-combinations at the
breakpoints, possibly predisposing to the deletions (Fig. 3; Supp.
Table S7). So far, SVs have been detected in a selection of other
known retinal dystrophy genes, such as PCDH15 and EYS [Le
Guedard et al., 2007; Pieras et al., 2011]. It can even be expected that
the occurrence of heterozygous CNVs will be higher than initially
anticipated, mainly because of the current lack of proper detection
methods. For most retinal dystrophy genes, PCR or capture-based
MPS enrichment platforms followedby regular paired-end sequenc-
ing have now been developed. It is, however, still a challenge to
perform CNV analysis solely based on coverage calculations. Mate-
pair sequencing or whole-genome sequencing aremore appropriate
MPS methods for this purpose.
Conclusion
This study is the first to identify 5′UTR single-base mutations in
NMNAT1-related LCA, and autosomal-recessive blindness in gen-
eral. In addition, we uncovered two distinct heterozygous CNVs
in NMNAT1, further expanding the complex mutation spectrum
of this gene. Hence, it can be anticipated that the high number of
patients with hidden genetic variation in which, for instance, only
a single heterozygous mutation has been found, can be explained
by regulatory mutations or SVs of NMNAT1, requiring additional
strategies apart from resequencing of the NMNAT1 coding region.
Finally, our study illustrates a paradigm shift from coding muta-
tions to noncoding, regulatory mutations and repeat-mediated SVs
in the molecular pathogenesis of unexplained cases of highly het-
erogeneous recessive disorders such as hereditary blindness.
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